Interv Akut Kardiol. 2014;13(1):28-30

The position of rivaroxaban in current medicine

Jiří Slíva
Ústavy farmakologie 2. a 3. LF UK, Praha

Novel anticoagulants (NOACs) present a huge step forward in better prevention and treatment of pathologic conditions associated with

increased coagulation. Their administration is characterized by better predictability of particular effect and lower incidence of adverse

drug reactions. The following article, based on so far published clinical trials, is focusing on the mapping of up-to-date knowledge about

direct inhibitor of activated factor Xa, rivaroxaban.

Keywords: xabans, rivaroxaban, venous thromboembolism, atrial fibrillation

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. The position of rivaroxaban in current medicine. Interv Akut Kardiol. 2014;13(1):28-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol.Ther. 2005; 78: 412-421. Go to original source... Go to PubMed...
    2. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013; 52: 243-254. Go to original source... Go to PubMed...
    3. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur.J Clin Pharmacol. 2005; 61: 873-880. Go to original source... Go to PubMed...
    4. Xu XS, Moore K, Burton P, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br.J.Clin Pharmacol. 2012; 74: 86-97. Go to original source... Go to PubMed...
    5. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775. Go to original source... Go to PubMed...
    6. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39. Go to original source... Go to PubMed...
    7. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. Go to original source... Go to PubMed...
    8. Beyer-Westendorf J, Lutzner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J.Thromb.Haemost. 2012; 10: 2045-2052. Go to original source... Go to PubMed...
    9. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb.J. 2013; 11: 21. Go to original source... Go to PubMed...
    10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N.Engl.J.Med 2011; 365: 883-891. Go to original source... Go to PubMed...
    11. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J.Am. Coll.Cardiol. 2013; 61: 1998-2006. Go to original source... Go to PubMed...
    12. Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur.Heart J. 2013. Go to original source...
    13. Chang CJ, Chen YC, Lin YK, Huang JH, Chen SA, Chen YJ. Rivaroxaban modulates electrical and mechanical characteristics of left atrium. J.Biomed.Sci. 2013; 20: 17. Go to original source... Go to PubMed...
    14. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38. Go to original source... Go to PubMed...
    15. Fitchett DH. Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel.Ther. 2012; 6: 349-357. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.